BioSpace News Archive

Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today detailed the results of its Phase 2 clinical trial (Study RM-202) of rivoceranib, an orally administered tyrosine kinase inhibitor (TKI), in patients with progressive recurrent or metastatic adenoid cystic carcinoma (R/M ACC).

Following continued international expansion in Q1 2022, QT Imaging, Inc. announced its intention to become a public company this year through a de-SPAC transaction.

New data from a mechanism of action study and new analyses of the global registration program for Eli Lilly and Company’s (NYSE: LLY) Mounjaro™ (tirzepatide) injection were presented at the American Diabetes Association’s® (ADA) 82nd Scientific Sessions®.

iNtRON Biotechnology (“iNtRON” or “Company”) announced today that the company has successfully completed the GLP toxicology studies of BAL200.

scentage Pharma announced that it has released the updated results from a Phase II study of the MDM2-p53 inhibitor alrizomadlin plus pembrolizumab in adults and children with various solid tumors in a Poster Discussion session at the 58th American Society of Clinical Oncology Annual Meeting.

Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced interim data from the innovaTV 205 trial, which included data evaluating tisotumab vedotin (TIVDAK®) in combination with pembrolizumab (Cohort E) in patients with recurrent or metastatic cervical cancer.

SOPHiA GENETICS (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, provides an update on its multimodal DEEP-Lung-IV clinical study (NCT04994795) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Ultima Genomics, Inc. today unveiled a broad collaboration with NVIDIA that leverages AI-accelerated analysis across multiple stages of the DNA sequencing and analysis process.

Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, announced that Todos Medical President and CEO Gerald Commissiong will present at the LD Micro Conference on June 8, 2022.

Valent BioSciences LLC announced that it has approved a major expansion of its biorational manufacturing facility in Osage, Iowa, which will meet increasing demand for its biorational products and the introduction of new products requiring more capacity.